NervGen Q3 net loss widens 36% to C$6.4 million
NGEN•NervGen’s third-quarter 2026 net loss widened 36% year over year to C$6.4 million. It reported C$80.1 million in cash, expected to fund operations through RESTORE’s anticipated first-half 2028 topline readout.




